G
Ghayas C Issa
Researcher at Harvard University
Publications - 110
Citations - 3071
Ghayas C Issa is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 11 publications receiving 2325 citations. Previous affiliations of Ghayas C Issa include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore,Ghayas C Issa,Madeleine E. Lemieux,Peter B. Rahl,Junwei Shi,Hannah M. Jacobs,Efstathios Kastritis,Timothy Gilpatrick,Ronald M. Paranal,Jun Qi,Marta Chesi,Anna C. Schinzel,Michael R. McKeown,Timothy P. Heffernan,Christopher R. Vakoc,P. Leif Bergsagel,Irene M. Ghobrial,Paul G. Richardson,Richard A. Young,William C. Hahn,William C. Hahn,Kenneth C. Anderson,Andrew L. Kung,James E. Bradner,Constantine S. Mitsiades +24 more
TL;DR: In this paper, a small-molecule bromodomain inhibitor, JQ1, was used to identify BET proteins as regulatory factors for c-Myc oncoprotein.
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore,Ghayas C Issa,Madeleine E. Lemieux,Peter B. Rahl,Junwei Shi,Hannah M. Jacobs,Efstathios Kastritis,Timothy Gilpatrick,Ronald M. Paranal,Jun Qi,Marta Chesi,Anna C. Schinzel,Michael R. McKeown,Timothy P. Heffernan,Christopher R. Vakoc,P. Leif Bergsagel,Irene M. Ghobrial,Paul G. Richardson,Richard A. Young,William C. Hahn,William C. Hahn,Kenneth C. Anderson,Andrew L. Kung,James E. Bradner,Constantine S. Mitsiades +24 more
TL;DR: Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathologic activation of c-Myc.
Journal ArticleDOI
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
Sangeetha Venugopal,Koichi Takahashi,Naval Daver,Abhishek Maiti,Gautam Borthakur,Sanam Loghavi,Nicholas J. Short,Maro Ohanian,Lucia Masarova,Ghayas C Issa,Xuemei Wang,Bueso-Ramos Carlos,Musa Yilmaz,Tapan M. Kadia,Michael Andreeff,Farhad Ravandi,Marina Konopleva,Hagop M. Kantarjian,Courtney D. DiNardo +18 more
TL;DR: In this paper , enasidenib and azacitidine (ENA + AZA) were combined with venetoclax (VEN) for IDH 2 mutated acute myeloid leukemia (IDH2 mut AML).
Journal ArticleDOI
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
Sangeetha Venugopal,Koichi Takahashi,Naval Daver,Abhishek Maiti,Gautam Borthakur,Sanam Loghavi,Nicholas J. Short,Maro Ohanian,Lucia Masarova,Ghayas C Issa,Xuemei Wang,Bueso-Ramos Carlos,Musa Yilmaz,Tapan M. Kadia,Michael Andreeff,Farhad Ravandi,Marina Konopleva,Hagop M. Kantarjian,Courtney D. DiNardo +18 more
TL;DR: In this article , enasidenib and azacitidine (ENA + AZA) were combined with venetoclax (VEN) for IDH 2 mutated acute myeloid leukemia (IDH2 mut AML).
Journal ArticleDOI
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz,Hagop M. Kantarjian,Nicholas J. Short,Patrick K. Reville,Marina Konopleva,Tapan M. Kadia,Courtney D. DiNardo,Gautam Borthakur,Naveen Pemmaraju,Abhishek Maiti,Elias Jabbour,Nitin Jain,Ghayas C Issa,Koichi Takahashi,Koji Sasaki,Maro Ohanian,Sherry Pierce,Guillin Tang,Sanam Loghavi,Keyur Patel,Sa A. Wang,Guillermo Garcia-Manero,Michael Andreeff,Farhad Ravandi,Naval Daver +24 more
TL;DR: In older/unfit newly diagnosed patients with acute myeloid leukemia (AML), lower intensity chemotherapy (LIC) in combination with either a FLT3 inhibitor or with venetoclax results in poor overall survival (median 8 to 12.5 months) as mentioned in this paper .